CDE Seeks Public Comment on Latest Generic Chemical Reference Preparations
The Center for Drug Evaluation (CDE), China’s regulatory body, is currently seeking public feedback on...
GSK’s Q1 2024 Results Beat Forecasts with 10% YOY Revenue Increase; Upgrades Full-Year Outlook
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the first...
Eli Lilly & Co. Raises Full-Year Guidance on Strength of Q1 2024 Results and Production Expansion
Eli Lilly & Co. (NYSE: LLY) has reported financial results for the first quarter of...
Pfizer Appoints Citigroup’s Andrew Baum as Executive Vice-President for Strategy and Innovation
Pfizer Inc. (NYSE: PFE) has announced the appointment of Andrew Baum, M.D., to serve as...
EyePoint Pharmaceuticals’ Durvayu Fails to Meet Primary Endpoint in NPDR Trial
EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT) has announced that its drug candidate Durvayu (vorolanib intravitreal insert;...
Pfizer’s Q1 2024 Results Highlight Robust Portfolio Growth and Profitability
Pfizer Inc. (NYSE: PFE) saw its share price surge over 5% following the release of...
US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies
On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity”...
Kelun-Biotech’s RET Inhibitor A400 Advances to Phase II Trial with FDA Approval
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, has announced that its...
Everest Medicines’ Nefecon Secures Market Approval for IgAN Treatment in Hong Kong
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, announced that it has received market approval...
Wondfo Biotech’s WELLlife Test Kit Receives FDA Nod for Home Use in the US
Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a leading biotechnology company based in China, has...
United Imaging’s uMR Jupiter 5T Becomes First Ultra-High Frequency MRI System to Gain FDA Approval
Shanghai-based medical equipment manufacturer United Imaging Healthcare (UIH, SHA: 688271) has announced that it has...
HuidaGene’s MECP2 Duplication Syndrome Therapy Earns Positive EMA Opinion
HuidaGene (Shanghai) Biotechnology Co., Ltd, a biotech company based in China, has announced that it...
Hansoh Pharmaceutical Secures Exclusive Rights to QYuns Therapeutics’ QX004N in Greater China
Jiangsu QYuns Therapeutics Co., Ltd, a biopharmaceutical company based in China, has entered into a...
Well Lead Medical’s Stone Removal Sheath Gains Karl Storz as US Sole Agent
Well Lead Medical Co., Ltd (SHA: 603309), a Guangzhou-based specialist in medical catheters, has entered...
Shenzhen Hepalink Logs 5.55% Q1 Revenue Growth and 133% Net Profit Increase
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the...
Zhejiang Hisun Pharmaceutical’s Ex-President Li Yan Investigated for Graft
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a Chinese pharmaceutical company, has announced that Li...
Jacobio Pharma’s Glecirasib Shows Promise in Phase II Study for NSCLC Presented at ASCO
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the presentation of...
BeiGene’s Anti-PD-1 Therapy Tislelizumab Expands Indication for Gastric Cancer in China
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that its anti-PD-1 therapy, tislelizumab, has...
China’s National Procurement Office Announces Continuous VBP for Joint Prosthetics
The National High-Value Medical Consumables Joint Procurement Office in China has initiated a new round...
China’s NMPA Approves Shenzhen Chipscreen’s Chidamide for DLBCL Indication
Shenzhen Chipscreen Biosciences Co., Ltd, a biopharmaceutical company based in China, announced that it has...